Doravirine/islatravir, sold under the brand name Idvynso, is fixed-dose combination medication used for the treatment of HIV/AIDS. It contains, doravirine, a HIV-1 non-nucleoside reverse transcriptase inhibitor; and islatravir, a nucleoside analog reverse transcriptase inhibitor. It is taken by mouth.
Medical uses Doravirine/islatravir is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine.
Society and culture Legal status The combination doravirine/islatravir was approved for medical use in the United States in April 2026.
Names The combination doravirine/islatravir is sold under the brand name Idvynso.
References
External links